The care of inflammatory bowel disease has changed considerably with the introduction of a
number of immunosuppressants including anti-metabolite and anti-TNF therapies. While …

Children and adolescents with inflammatory bowel disease (IBD) receiving therapy with
tumor necrosis factor α inhibitors (anti-TNFα) pose a unique challenge to health care …

Purpose The anti-tumor necrosis factor (TNF) agents infliximab (IFX) and adalimumab (ADA)
have been recently introduced to treat severe inflammatory bowel disease (IBD) that is …

Objectives: Adalimumab, a humanised anti‐tumour necrosis factor antibody, is an effective
treatment in adult patients with refractory Crohn disease (CD). The available literature on its …

Objective: The antitumor necrosis factor α (TNFα) antibodies infliximab and adalimumab are
effective in inducing and maintaining remission in pediatric patients with Crohn disease …

The treatment goal for children suffering from inflammatory bowel disease has been
evolving with biologic therapies like anti-tumor necrosis factor agents assuming a more …

Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics employed in
the treatment of patients with inflammatory bowel disease (IBD). Adalimumab is the first fully …

Introduction Crohn's disease (CD) is a chronic and progressive disease in which the long-
term management is important. This study sought to assess treatment persistence and dose …

Tumor necrosis factor-a (TNF) is a key pro-inflammatory cytokine in Crohn disease (CD). 1
Produced mainly by activated macrophages and T lymphocytes, TNF induces many other …

The exact role of biologics in the treatment of pediatric psoriasis remains undefined but is
evolving. Biologics are an attractive option for use in children in part because they offer more …